Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2003 1
2004 6
2005 9
2006 29
2007 21
2008 20
2009 36
2010 27
2011 45
2012 46
2013 41
2014 56
2015 56
2016 59
2017 56
2018 65
2019 46
2020 53
2021 58
2022 37
2023 31
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

728 results

Results by year

Filters applied: . Clear all
Page 1
Rotarix: vaccine performance 6 years postlicensure.
O'Ryan M, Lucero Y, Linhares AC. O'Ryan M, et al. Expert Rev Vaccines. 2011 Dec;10(12):1645-59. doi: 10.1586/erv.11.152. Expert Rev Vaccines. 2011. PMID: 22085167 Review.
Rotarix() was first licensed in 2004 and rapidly introduced into private and public markets worldwide. In a previous 2009 article, we reviewed the impact of rotavirus-associated disease, the rationale for different vaccines, prelicensure efficacy studies and cost-effective …
Rotarix() was first licensed in 2004 and rapidly introduced into private and public markets worldwide. In a previous 2009 article, we …
Rotarix: a rotavirus vaccine for the world.
Ward RL, Bernstein DI. Ward RL, et al. Clin Infect Dis. 2009 Jan 15;48(2):222-8. doi: 10.1086/595702. Clin Infect Dis. 2009. PMID: 19072246 Review.
The US Food and Drug Administration approved the RIX4414 vaccine for use in the United States in April 2008. This vaccine has been found to provide a reduction in the incidence of severe rotavirus disease of >80% in all trials including a developing country. ...T …
The US Food and Drug Administration approved the RIX4414 vaccine for use in the United States in April 2008. This vaccine has …
Rotarix in Japan: Expectations and Concerns.
Nakagomi O, Nakagomi T. Nakagomi O, et al. Biol Ther. 2011 Dec 14;1(1):4. doi: 10.1007/s13554-011-0007-5. eCollection 2011. Biol Ther. 2011. PMID: 24392294 Free PMC article. Review.
While Rotarix contains only a single G1P[8] human rotavirus, the postlicensure studies in Brazil showed that Rotarix provided a 75%-85% protective efficacy against severe dehydrating diarrhea or hospitalizations due to fully-heterotypic G2P[4] strains. While postlic …
While Rotarix contains only a single G1P[8] human rotavirus, the postlicensure studies in Brazil showed that Rotarix provided …
Dynamics of G2P[4] strain evolution and rotavirus vaccination: A review of evidence for Rotarix.
Bibera GL, Chen J, Pereira P, Benninghoff B. Bibera GL, et al. Vaccine. 2020 Jul 31;38(35):5591-5600. doi: 10.1016/j.vaccine.2020.06.059. Epub 2020 Jul 7. Vaccine. 2020. PMID: 32651115 Free article. Review.
This comprehensive literature review aims to provide an insight on RV genotype evolution in the context of mass vaccination with Rotarix, particularly in the case of G2P[4]. In the post-vaccine era, strain surveillance data indicated temporal and spatial changes in countri …
This comprehensive literature review aims to provide an insight on RV genotype evolution in the context of mass vaccination with Rotarix …
Update on Rotarix: an oral human rotavirus vaccine.
O'Ryan M, Linhares AC. O'Ryan M, et al. Expert Rev Vaccines. 2009 Dec;8(12):1627-41. doi: 10.1586/erv.09.136. Expert Rev Vaccines. 2009. PMID: 19943758 Review.
It provided 85-96% protection against severe rotavirus gastroenteritis caused by G1 and non-G1 serotypes in Latin American and European clinical trials; and of public health importance, Rotarix reduced hospitalizations of all-cause gastroenteritis by 40 and 75%, respective …
It provided 85-96% protection against severe rotavirus gastroenteritis caused by G1 and non-G1 serotypes in Latin American and European clin …
Live attenuated human rotavirus vaccine, Rotarix.
Bernstein DI. Bernstein DI. Semin Pediatr Infect Dis. 2006 Oct;17(4):188-94. doi: 10.1053/j.spid.2006.08.006. Semin Pediatr Infect Dis. 2006. PMID: 17055369 Review.
This review provides a summary of the rationale, development, and evaluation of one of these vaccines, Rotarix. Rotarix is a live oral rotavirus vaccine developed from a single protective human strain following multiple passages in tissue culture to attenuate the st …
This review provides a summary of the rationale, development, and evaluation of one of these vaccines, Rotarix. Rotarix is a l …
728 results